Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,113

The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

Heidbuchel, Hein, Verhamme, Peter, Alings, Marco, Antz, Matthias, Diener, Hans-Christoph, Hacke, Werner, Oldgren, Jonas, Sinnaeve, Peter, Camm, A. John, Kirchhof, Paulus·2015·Europace
DOI 10.1093/europace/euv309
Open this paper in CoChat — free account

Abstract

The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-106]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical situations remain. The European Heart Rhythm Association set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group defined what needs to be considered as 'non-valvular AF' and listed 15 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 15 topics are (i) practical start-up and follow-up scheme for patients on NOACs; (ii) how to measure the anticoagulant effect of NOACs; (iii) drug-drug interactions and pharmacokinetics of NOACs; (iv) switching between anticoagulant regimens; (v) ensuring adherence of NOAC intake; (vi) how to deal with dosing errors; (vii) patients with chronic kidney disease; (viii) what to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a risk of bleeding?; (xi) management of bleeding complications; (x) patients undergoing a planned surgical intervention or ablation; (xi) patients undergoing an urgent surgical intervention; (xii) patients with AF and coronary artery disease; (xiii) cardioversion in a NOAC-treated patient; (xiv) patients presenting with acute stroke while on NOACs; and (xv) NOACs vs. VKAs in AF patients with a malignancy. Additional information and downloads of the text and anticoagulation cards in >16 languages can be found on an European Heart Rhythm Association web site (www.NOACforAF.eu).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/europace/euv309

Cites

241 of 241 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 241 references

Research works printed but not linked: 23

  1. 10.1160/TH14-06-0564 · doi:10.1160/th14-06-0564
  2. 10.1016/S0735-1097(14)60325-9 · doi:10.1016/s0735-1097(14)60325-9
  3. Matsushima N Lee F Sato T Weiss D Mendell J . Absolute Bioavailability of Edoxaban in Healthy Subjects. The AAPS Journal 2011;13 (Suppl):S2. (abstract).
  4. Frost C Yu Z Nepal S Bragat A Moore K Shenker A Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 2008;48:1132 (abstract).
  5. Vakkalagadda B Frost C Wang J Nepal S Schuster A Zhang D Effect of rifampicin on the pharmacokinetics of apixaban, on oral direct inhibitor of factor Xa. J Clin Pharmacol 2009;49:1124 (abstract).
  6. Frost C Boyd RA . The contribution of apixaban renal clearance to total clearance. J Thromb Thrombolysis 2015; doi:10.1007/s11239-015-1220-8 doi:10.1007/s11239-015-1220-8. · doi:10.1007/s11239-015-1220-8
  7. Kubitza D Becka M Zuehlsdorf M Mueck W . No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006;46:702 (Abstract 11). · DOI · Paper page
  8. 10.1111/bcp.12075 · DOI · Paper page
  9. 10.1124/dmd.113.053769 · doi:10.1124/dmd.113.053769
  10. Mendell J Noveck R Zahir H Lee F Petrushin V Rubets I The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics. Basic Clin Pharmacol Toxicol 2010;107:2848. (Abstract).
  11. Pan X Kachroo S Liu X Kawabata H Phatak H . Discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tale of first 200 days. Eur Heart J 2014;35 (Abstract Supplement):897. · doi:10.1016/s0735-1097(14)60415-0
  12. Chang M Shenker A Wang J Yu Z Pursley J Boyd R Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Clin Pharmacol Drug Dev 2012;1:185.
  13. Ridout G de la Motte S Niemczyk S Sramek P Johnson L Jin J Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model. J Clin Pharmacol 2009;49:1124. (abstract).
  14. 10.1016/j.cjca.2014.01.015 · doi:10.1016/j.cjca.2014.01.015
  15. Wang X Tirucherai G Ehlgen A Wang J Chang M Zhang D Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev 2012;1:187.
  16. Perlstein I Wang Z Song Y Wang J Bedford B Chang M Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects. Blood 2014;124:345. · doi:10.1182/blood.v124.21.345.345
  17. 10.1093/europace/eut296 · doi:10.1093/europace/eut296
  18. 10.1093/europace/eut353 · doi:10.1093/europace/eut353
  19. 10.1016/j.amjcard.2012.12.046 · DOI
  20. Jennings JM Robichaux R McElderry HT Plumb VJ Gunter A Doppalapudi H Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electrophysiol 2013;24:1125–9. · doi:10.1111/jce.12214
  21. 10.1093/europace/eut423 · doi:10.1093/europace/eut423
  22. 10.1007/s003920050171 · doi:10.1007/s003920050171
  23. 10.1016/j.ahj.2014.12.020 · doi:10.1016/j.ahj.2014.12.020

Cited by

See all 1,113

Metadata

Authors
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P.
Venue
Europace
Publisher
Oxford University Press (OUP)
Published
2015-08-31
Volume
17
Issue
10
Pages
1467-1507
ISSN
  • 1099-5129 (ISSN-L)
  • 1532-2092
DOI
10.1093/europace/euv309
OpenAlex
W1834574045
Cited by
1,113
References
241
FWCI
151.24
Type
journal article
Language
en
Open access
closed
Funders
  • Bayer Pharma AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Pfizer Alliance and Daiichi-Sankyo Europe

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. https://app.cochat.ai/papers/10.1093/europace/euv309
The paper
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015). Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. https://doi.org/10.1093/europace/euv309

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.